ArticleAnnals of medicine2025
Clinical characteristics of tracheobronchial mucormycosis: a retrospective analysis of twenty cases.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pulmonary mucormycosis with endobronchial involvement due toMedical mycology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTracheobronchial mucormycosis (TM) is a rare and potentially fatal disease commonly occurred in immunocompromised individuals, with death risk from massive hemoptysis or asphyxia.To enhance clinical understanding, we retrospectively analyzed the clinical features, therapeutic regimen, and outcomes of TM patients.
methodsWe conducted a comprehensive analysis of hospitalized patients diagnosed with TM between January 1, 2010, and April 30, 2025, systematically collecting and evaluating data on clinical manifestations, treatment strategies, and clinical outcomes.
resultsTwenty patients were included in this study, with a median age of 56 years. Most patients had diabetes mellitus, followed by those with hematological malignancies. Common symptoms included cough, expectoration, hemoptysis, and fever. Chest CT revealed pulmonary infiltrates, bronchial stenosis or occlusion, obstructive pneumonia, and pleural effusion, while bronchoscopy revealed neoplasms, purulent secretions, and bronchial obstruction or stenosis.Metagenomic next-generation sequencing demonstrated a higher positive diagnostic rate and shorter time to diagnosis compared to histopathology and culture. Three patients received intravenous amphotericin B (AmB) monotherapy, eight patients were treated with a combination of intravenous and intratracheal AmB, one patient was treated with intravenous triazole drug alone, two patients received a regimen consisting of intravenous triazole drugs combined with intratracheal AmB, and five patients underwent triple therapy involving both intravenous triazole drugs and concurrent intravenous and intratracheal AmB administration. Additionally, one patient underwent bronchoscopic intervention, and two patients underwent lobectomy. Fourteen patients demonstrated clinical improvement, whereas six died. Massive hemoptysis was the leading cause of mortality.
conclusionsTM is a highly lethal disease that is often underdiagnosed. Bronchoscopy plays an essential role in both diagnosis and management. Systemic antifungal therapy, combined with intratracheal administration of AmB, has shown favorable therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.